 Aim: To determine the safe dose of lenvatinib that can be co-administered with letrozole in a phase Ib study, followed by a phase II study to determine the efficacy of lenvatinib letrozole in post-menopausal patients newly diagnosed with hormone receptor positive breast cancer in the neoadjuvant setting. 